ATRX and neuroblastoma: Neuroblastoma cells with ATRX LoF also show decreased chromatin accessibility at neuronal differentiation genes following treatment with 13-cis-retinoic acid (RA) - an agent used as standard-of-care in the minimal residual disease setting to prevent neuroblastoma relapse.